Skip to main content

Recent News

57 yoBM advertising executive (w/ comorbidities) has insidious & progressive myalgias and weakness - arms and legs; most likely Dx?

Dr. John Cush @RheumNow (  View Tweet)

Wrist pain differential diagnoses beautifully demonstrated đź‘Ť Remamber that radial-sided wrist pain is more common that ulnar-sided wrist pain. https://t.co/3Ite2FsYtl
Dr. OMID BANDARCHI @OBandarchi (  View Tweet)
Predicting Vasculitis Relapse Scores on a patient-reported sino-nasal symptom questionnaire were associated with subsequent flares of one type of ANCA-associated vasculitis (AAV), researchers said. https://t.co/2IjrXiGbIA https://t.co/4uTsa6mc77
Dr. John Cush @RheumNow (  View Tweet)
Chikungunya Arthritis - 2 studies show benefit of dexamethosone (up to 4mg/d) w/ improved DAS28 scores; Uncertain benefit however with MTX; 133 Brazilian pts studied for 5 mos & 31 pts studied for 8wks. https://t.co/Ko3aRYX0xi https://t.co/rtC4RCRjnU https://t.co/XOoFYw0dR4
Dr. John Cush @RheumNow (  View Tweet)
Long term outcomes of phase III KEEPsAKE 2 trial in #PsA; SC risankizumab 150 mg given q12wks (after wk 24). 78% were ongoing. RZK achieved 60% ACR20 at wk 52, 57% ACR20 at wk 100, & 75% maintained ACR20 to wk 100. MDA achieved in 34% & 33%.https://t.co/juYQklrhG3 https://t.co/8uhmydPZDf
Dr. John Cush @RheumNow (  View Tweet)

ACR Supports FY 2024 Budget

ACR

The American College of Rheumatology (ACR) today expressed strong support for several key measures included in the Fiscal Year (FY) 2024 budget.

Read Article
Cabaletta Bio announced FDA has granted Orphan Drug Designation to CABA-201, a 4-1BB-containing human CD19-CAR T cell agent, to treat systemic sclerosis. RESET (REstoring SElf-Tolerance) trial program includes the Phase 1/2 RESET-SSc trial https://t.co/SWAwLs4PzG https://t.co/3yJ8zlhN9C
Dr. John Cush @RheumNow (  View Tweet)
Norwegian Institute of Public Health found that among more than 10,000 adults, those who were physically active had a higher pain tolerance than those who were sedentary; and the higher the activity level, the higher the pain tolerance. https://t.co/yH6kckcBTA https://t.co/BlCXV0VjP2
Dr. John Cush @RheumNow (  View Tweet)
Korean biologics registry study 526 Ank Spondylitis pts on TNFi > 1yr and tapered; 24.1% experienced flares. Predictors of flare included B27+, inflammatory LBP, psoriasis, SpA Fam Hx, DM, ≥50% TNFi tapering, Dz activity (ASDAS-CRP, BASFI) at tapering https://t.co/Pila2PBlpN https://t.co/WgF9UtfTiR
Dr. John Cush @RheumNow (  View Tweet)
GEM: Your Clinic Desk needs to be where you can see your patients enter/walk/rise into the clinic. Also pts can see where you work. They learn you & you learn them in ways not gleaned from the exam room https://t.co/WfFqiuztW1
Dr. John Cush @RheumNow (  View Tweet)
Window of Opportunity in Psoriatic Arthritis A Dutch Early Psoriatic Arthritis cohort study shows that psoriatic arthritis (PsA) patients treated early (referred and diagnosed within in less than 12 weeks) had the best clinical outcomes. https://t.co/mbftcq1dv8 https://t.co/VYNtByK9l0
Dr. John Cush @RheumNow (  View Tweet)
Secondary Sjogren’s Ups Rheumatoid Arthritis Severity A Swiss observational study has shown that RA patients with concomitant Sjögren’s disease (SjD) are more likely to have a severe RA phenotype, and be less responsive to treatment. https://t.co/CZqLO2GSeM https://t.co/VyLKvUIfJ9
Dr. John Cush @RheumNow (  View Tweet)

Predicting Vasculitis Relapse

MedPage Today

Scores on a patient-reported sino-nasal symptom questionnaire were associated with subsequent flares of one type of ANCA-associated vasculitis (AAV), researchers said.

Read Article
Obesiy (& Visceral abdominal fat) in Ankylosing Spondylitis is assoc w/ worse Dz activity, funct disability, & spinal mobility in study of 74 radiographic axSpA treated with bDMARDs. https://t.co/Z5e9cU62nS https://t.co/fD9lhj085B
Dr. John Cush @RheumNow (  View Tweet)
High Mortality & complication rates seen in 53 #RA pts presenting w/ Periprosthetic joint infection - 54 PJI w/ avg age 65 yrs (32-88); mortality rate was 19%. Most common was Staphylococci (63%), w/ 20% w/ multiorganism infx & 6 C/S neg https://t.co/Syrm5qPKDQ https://t.co/bnMfMLmFJ7
Dr. John Cush @RheumNow (  View Tweet)
BIOBADASER registry 1128 RA pts Rx w/ 1st ts/bDMARD, Among the 9.3% w. multimorbidity they noted higher DAS28 dz activity, but no differences in ts/bDMARD retention rates betw those w/ and without multimorbidity https://t.co/hZDpceuOFq https://t.co/pxSg6rKNNr
Dr. John Cush @RheumNow (  View Tweet)
Korean claims study of #RA & pregnancy (& adverse preg outcomes (APO), shows MTX or LEF use w/in 3 mos of conception assoc w/ incr. in APOs (aOR 2.14-.68). In 5728 preg: 1152 APOs, HCQ most commonly used, DMARD use decreased during preg. https://t.co/fGRZS5ID4A https://t.co/LXaaVYcFsh
Dr. John Cush @RheumNow (  View Tweet)
Post-COVID MDs spend more time on EHR mostly messaging w/ patients, with a 157% increase from prepandemic average. Each additional patient message was associated with a 2.32-min increase in EHR time per day (P < .001), mostly messaging https://t.co/yfPM3vTmRo https://t.co/XVwC50CH2C
Dr. John Cush @RheumNow (  View Tweet)
Naysayers & Disrupters Dr. Jack Cush reviews the news and journal reports from the past week - including a few contrary reports on infection, seropositivity and plasmapheresis. https://t.co/tm3V8U7pv4 https://t.co/R8U04urRXg
Dr. John Cush @RheumNow (  View Tweet)
Autoimmune dz pts have higher risk of macular degeneration. Cleveland Clinic study of 200K AMD vs controls, finds: - SLE (RR 1.73) - Scleroderma (1.65) - Psoriasis (1.48) - Vasculitis (1.48) - RA (1.4) - UC &CD (~1.42) - Sarcoid (1.42) https://t.co/RKyriK1zPe https://t.co/9F7N1jHKxX
Dr. John Cush @RheumNow (  View Tweet)